Navigation Links
Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
Date:10/8/2008

CALGARY, Oct. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully completed initial scale up of its manufacturing process for REOLYSIN(R) to commercial scale.

The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada.

"Our existing manufacturing capacity at 40 litres allows us to support future pivotal clinical studies with REOLYSIN(R)," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "Using this process, a 100-litre manufacturing facility has the potential to produce more than one million doses a year for intravenous use."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process, the transfer of the scale up to full cGMP production, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and developme
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24 Sigma-Aldrich Corpora...SDAQ OMX conference on Tuesday, December 1st at 1:...rties may listen via live audio broadcast over the...m a a ldrich.com/ . Users can click the "Webc...ma-Aldrich: Sigma-Aldrich is a leading Life Scie...
(Date:11/24/2009)...YKJAVIK, Iceland, November 24 /PRNewswire-FirstCal...announced the approval of all of its,"first day" m...ct of Delaware,(the "Bankruptcy Court"). deCODE la...r Chapter 11 of the United States Bankruptcy Code ...ssued by the Bankruptcy Court allow the company to...
(Date:11/24/2009)...f., Nov. 24 NeurogesX, I...focused on developing and commercializing novel pa...ony DiTonno, President and Chief Executive Officer... Jaffray Health Care Conference, to be held Decemb...ork, New York. ,, Mr. DiTonno and Stephen Ghig...
(Date:11/24/2009)...RNewswire/ -- Blue Marble Energy Corp. announced t...pment Authority (OPDA) were recently awarded $2 mi...italization Board (CERB) in a private/public partn...ochemical biorefinery in Lincoln County, WA. ,...evelopment of our biorefinery and bring over 70 gr...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...ust 28 Strong organic,growth continued in Q2 2008...development of Exiqon,s first molecular diagnostic... for year end launch., - Revenue in Q2 2008 incr...8 million, totaling DKK 44.5 million in the first ...ncreased by 239% on the same period last year to ...
...olcano Corporation,(Nasdaq: VOLC ), a leading man...d (IVUS), functional measurement (FM) and Optical ...hance the diagnosis and treatment,of coronary and ...ll be,participating in the Thomas Weisel Partners ...4., The presentation by Scott Huennekens, preside...
...ance, August 28 , - Hubert Sagnieres Appointed Ch...rectors of Essilor International today appointed H...ve alongside Xavier Fontanet,Chief Executive Offic..., A graduate of Ecole Centrale in Lille and holde...silor in 1989 as President of International,Market...
Other Biology Technology:Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited) 2Volcano Presentation at Thomas Weisel Conference to Be Webcast 2
(Date:11/26/2009)... at last worked out a way of using recordings of b...ulations. This is the first time sound recordings ...accurate estimates of bird species, populations. B...Ecological Society,s Journal of Applied Ecology ,...a major advance in our ability to monitor whale an...
(Date:11/26/2009)...in-resistant Staphylococcus Aureus ) and other dr...ow-temperature plasma prototype devices have been ... bactericidal cocktails. , Two prototype devices...on of healthy skin (e.g. hands and feet) in hospit...thal threat; and another to shoot bacteria-killing...
(Date:11/25/2009)..., firefighters, police officers and ambulance work...Trade Center complex. They battled to save people ...ivors, tackled fires and evacuated as many people ...ted 17,000 people. And making their jobs even hard...ned workers and their relatives jammed mobile netw...
Breaking Biology News(10 mins):Ecologists sound out new solution for monitoring cryptic species 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 1Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 2Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 3Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 4Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 5Grifols Breaks Ground on New National Testing Laboratory 14506 1Grifols Breaks Ground on New National Testing Laboratory 14506 2U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 1U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 2U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 3U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 4
...l be brought to the marketplace, giving laboratori... organisms. EMBLEM Technology Transfer GmbH (EMBLE...r Biology Laboratory (EMBL), announced today that ...leader Carl Zeiss to commercialize a new technolog...copy). , "Microscopes have to evolve to keep up wi...
...of Reproduction contains a report of some intrigui...i from one genus of fish were transplanted to enuc... offspring, cloned from nuclei of common carp and ...l to the nuclear donor species, Cyprinus carpio, i...er of vertebrae in the clones, however, was in the...
...nce and drug development : only "lucrative","marke...casions I,ve,seen very promising drugs candidates ...s to be made with it, even if millions would have,...this fate is to find,a drug candidate that affect ...fitable" one. PLoS Medecine has an article about a...
Other Biology News:The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2
...reedom EVOlyzer is Tecans new Enzyme-Linked Immuno...mated microplate processing. Freedom EVOlyzer is a...ng and includes state-of-the art reader, washer an...ed EVOlyzer software. The Freedom EVOlyzer is avai...
...ins are polypeptide hormones which belong to the t... TGF- superfamily is a large group of extra-cellul...velopment, reproductive function and tumor formati...etic proteins, growth differentiation factors, AMH...
...read Plating Beads Sterile plating in just secon...rdous ethanol flaming, More uniform spreading and...le packaging: dispenser bottle for spreading 100 p...t and easiest way to spread cells on multiple plat...
...aboratories working in a regulated environment, Pi...software that automates gravimetric pipette calibr...eets todays regulatory compliance requirements. Pi...es a full security implementation, support for Ora...
Biology Products: